Birmingham scientists using novel hydrogel to create ‘lollipops’ for mouth cancer diagnostic

The biocompatible hydrogel concentrates and labels proteins in a single step, so is suittable for detecting low abundance proteins from small sample sizes.

Doctor examining patient

Around 12,400 people are diagnosed with cancers of the head and neck in the UK every year.

Researchers from the University of Birmingham, U.K., have received funding from Cancer Research UK and the Engineering and Physical Sciences Research Council to create a new ‘lollipop’ diagnostic for mouth cancer using a novel smart hydrogel.

Developed by Dr Ruchi Gupta and colleagues from the School of Chemistry, the biocompatible hydrogel concentrates and labels proteins with a fluorescent marker in a single step, making it suitable for diagnostics that aim to detect low abundance proteins from small sample sizes.

The hydrogel achieves protein capture via the fluorescent marker (fluorescein isothiocyanate or FITC), which is attached to the hydrogel by a photocleavable bond. On exposure to light, the protein, which now attached to the flourescin, is released from the hydrogel.

Initial studies on the gel, published last year in the Royal Society of Chemistry’s Analyst journal, showed the gel offered a concentration factor of 236 with a reference protein (streptavidin), and 50% of the proteins in the hydrogel were released after 100 seconds exposure to UV light.

Diagnostics are new landscape for biogels, which until now have been used for drug delivery and tissue regeneration.

Beyond this project, we’re keen to investigate other possibilities for the hydrogel, and will welcome approaches from research or commercial organisations who want to collaborate on research or commercialisation.

Dr Ruchi Gupta, Associate Professor of Biosensors, School of Chemistry

The gel developed by Dr Gupta offers distinct benefits over existing diagnostic techniques. It has far fewer steps than ELISA based assays, or preconcentration using beads and electrophoresis, and can be conducted at room temperature.

Cancer Research Horizon’s, the innovation engine built to complement Cancer Research UK’s network has filed a patent application for the novel hydrogel, and the Birmingham researchers are seeking collaborators or partners to develop further applications.

The gel’s biocompatibility means the hydrogel can be used either in vitro, or directly on patients, as with the current project, which aims to replace current invasive, time-consuming diagnostic procedures that need to be conducted by medical professionals.

Dr Ruchi Gupta, Associate Professor of Biosensors at the University of Birmingham, said: “Smart hydrogels have really exciting potential for diagnosing mouth cancer. They can be easily moulded into shapes as a solid to “catch” proteins in saliva, and we’re hoping that we can be the first to make a device which is much kinder for diagnosing mouth cancer for patients and easier for GPs to use.

“Beyond this project, we’re keen to investigate other possibilities for the hydrogel, and will welcome approaches from research or commercial organisations who want to collaborate on research or commercialisation.”

Notes for editors

For media information contact Ruth Ashton, University of Birmingham Enterprise, email: r.c.ashton@bham.ac.uk.

Commercial, licensing, or IP enquiries should be directed to Martyn Bottomley, at Cancer Research Horizons, email: martyn.bottomley@cancer.org.uk

The University of Birmingham is ranked amongst the world’s top 100 institutions. Its work brings people from across the world to Birmingham, including researchers, teachers and more than 8,000 international students from over 150 countries.

University of Birmingham Enterprise helps students and researchers turn their ideas into new services, products and enterprises that meet real-world needs. We also provide incubation and bio-incubation, support innovators and entrepreneurs with mentoring, advice and training, and manage the University’s Academic Consultancy Service. Follow us on LinkedIn and Twitter.

About Cancer Research UK

  • Cancer Research UK is the world’s leading cancer charity dedicated to saving lives through research, influence and information.
  • Cancer Research UK’s pioneering work into the prevention, diagnosis and treatment of cancer has helped save millions of lives.
  • Cancer Research UK has been at the heart of the progress that has already seen survival in the UK double in the last 50 years.
  • Today, 2 in 4 people survive their cancer for at least 10 years. Cancer Research UK wants to accelerate progress and see 3 in 4 people surviving their cancer by 2034.
  • Cancer Research UK supports research into the prevention and treatment of cancer through the work of over 4,000 scientists, doctors and nurses.
  • Together with its partners and supporters, Cancer Research UK is working towards a world where people can live longer, better lives, free from the fear of cancer.

For further information about Cancer Research UK's work or to find out how to support the charity, please call 0300 123 1022 or visit www.cancerresearchuk.org. Follow us on Twitter and Facebook.